A clinical-stage oncology biotech firm advancing a pipeline of innovative immunotherapies to treat cancer with significant R&D investment and limited current cash reserves.
Early investors may gain significant upside if the company's pipeline achieves positive clinical trial results or secures major licensing partnerships that validate its technology platform. The recent financing activity provided a cash buffer, potentially extending the company's operational runway beyond current estimates. A successful proof-of-concept for their immunotherapies could transform the company into a valuable asset in the crowded oncology market.
The company faces existential risk due to its negative net income trend and substantial accumulated deficit of over $120M, limiting financial flexibility without further dilution. High operating expenses coupled with zero revenue create a precarious financial position where any setback in clinical trials could jeopardize the company's survival. Investors should be cautious given the limited cash reserves relative to the annual burn rate and the inherent volatility of clinical-stage biotechnology.
Calidi Biotherapeutics is a clinical-stage biotechnology company focused on developing proprietary immunotherapies and cancer treatments. The company operates primarily in the United States, targeting oncology markets with its pipeline of novel cell-based therapies. Currently, the company has no commercial revenue streams as it remains in the research and development phase.
The company reported a net loss of $22.2M in the latest period, driven by substantial operating expenses including $8.9M in R&D and $12.9M in G&A costs. While the company successfully raised $27.4M in cash flow from financing activities, ending with $9.6M in cash, the high burn rate relative to its balance sheet suggests a need for future capital raises or strategic partnerships. The shift from a 2022 profit of $3.5M to losses in 2023 and 2024 indicates a transition into an intensive development phase typical of early-stage biotech firms.
The global cell therapy market is experiencing rapid growth driven by advancements in immunotherapy and CAR-T technology, offering substantial potential for new entrants with innovative platforms. However, the sector is highly competitive with established players dominating the landscape, making it difficult for smaller companies to secure market share without proven clinical data. Regulatory scrutiny remains intense as agencies like the FDA evaluate safety profiles of novel cellular products before approval.
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Cost of Revenue | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 |
| Operating Expenses | $4.7M | $29.0M | $21.8M |
| Operating Income | $-4.7M | $-29.0M | $-21.8M |
| R&D | — | $13.0M | $8.9M |
| G&A | — | $16.0M | $12.9M |
| Stock-Based Comp | — | $4.8M | $3.0M |
| Depreciation | — | $392.0K | $402.0K |
| Other OpEx | — | $0 | $0 |
| Non-Operating Income | $8.5M | $-208.0K | $-419.0K |
| Pre-Tax Income | $3.9M | $-29.2M | $-22.2M |
| Income Tax | $347.0K | $16.0K | $14.0K |
| Continuing Ops | $3.5M | $-29.2M | $-22.2M |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $3.5M | $-29.2M | $-22.2M |
| Minority Interest | $0 | $0 | $-66.0K |
| Net to Common | $3.5M | $-29.2M | $-22.1M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $401.7K | $4.3M | $10.2M |
| Cash & Equivalents | — | — | $9.6M |
| Accounts Receivable | $870 | — | — |
| Prepaid Expenses | — | $2.4M | $636.0K |
| Other Current Assets | $400.8K | $1.9M | $-9.0K |
| Long-Term Assets | $42.5M | $5.7M | $4.0M |
| PP&E (Net) | — | $1.3M | $869.0K |
| Operating Leases | — | $4.1M | $2.9M |
| Other LT Assets | — | $373.0K | $152.0K |
| Total Assets | $42.9M | $10.0M | $14.2M |
| Current Liabilities | $4.5M | $10.2M | $9.5M |
| Accounts Payable | $51.1K | — | — |
| Current Debt | — | $807.0K | $3.2M |
| Current Leases | — | $1.0M | $1.2M |
| Other Current Liab | $1.3M | $8.4M | $5.1M |
| Long-Term Liabilities | $1.1M | $8.0M | $2.7M |
| LT Operating Leases | — | $3.0M | $1.8M |
| Other LT Liab | — | $5.0M | $873.0K |
| Total Liabilities | $5.6M | $18.3M | $12.2M |
| Shareholders' Equity | $37.2M | $-8.2M | $2.0M |
| Paid-In Capital | $0 | $91.4M | $123.3M |
| Retained Earnings | $-5.2M | $-99.6M | $-121.7M |
| AOCI | — | $-47.0K | $-28.0K |
| Total L&E | $42.9M | $10.0M | $14.2M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $3.5M | $-29.2M | $-22.2M |
| Non-Cash Adjustments | $-5.9M | $4.0M | $7.8M |
| Working Capital Changes | $2.5M | $-1.8M | $-5.3M |
| Cash from Operations | $98.1K | $-27.0M | $-19.7M |
| Cash from Investing | $187.7M | $-478.0K | $-16.0K |
| Cash from Financing | $-188.8M | $29.0M | $27.4M |
| FX Effect | $0 | $-6.0K | $-13.0K |
| Net Change in Cash | $-968.8K | $1.6M | $7.6M |
| Beginning Cash | $1.1M | $590.0K | $2.2M |
| Ending Cash | $93.9K | $2.2M | $9.8M |
The company's financial structure indicates operations are driven entirely by research and development expenses, specifically in research and development ($8.9M), general and administrative costs ($12.9M), and share-based compensation ($3.0M), with no commercial product sales or revenue generation yet.
Significant cash burn rate of approximately $22.2M annually with a retained earnings deficit of over $121M, raising concerns about runway sustainability. Lack of commercial revenue makes the company entirely dependent on future financing rounds or successful milestone achievements from its pipeline. Potential for regulatory hurdles in bringing novel cell therapies to market and uncertainty regarding clinical trial success rates.
Access to proprietary cell therapy technologies and platforms that may offer differentiated treatment options for cancer patients. Potential partnerships or licensing deals could provide non-dilutive funding streams in the future. Highly skilled scientific talent attracted by the company's focus on cutting-edge immunotherapy research.
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.